Q-omics provides the consensus-scored LDHAP4 profile across patient tissues and cancer cell-line models. LDHAP4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LDHAP4 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LDHAP4 RNA expression shows 17,362 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where LDHAP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDHAP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDHAP4 survival associations across molecular data types. LDHAP4 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDHAP4 RNA expression–survival associations across cancer types. High LDHAP4 expression shows unfavorable associations in HNSC, CESC, MESO, KICH and LUAD, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LDHAP4 RNA expression.
This table summarizes LDHAP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LDHAP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDHAP4 shows higher tumor expression in KIRC, COAD, LUAD, KIRP, HNSC and LUSC. The KIRC box plot shows higher LDHAP4 RNA expression in tumor versus normal tissue (log2 FC = +1.675, t-test p < 0.001).
This table shows molecular features associated with LDHAP4 in patient tissues and cancer cell lines. In patient samples, LDHAP4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
